To confirm our model’s ability to predict EC progression, we also analyzed the potential relationship between the risk genes (HSPA6, CACYBP, DKK1, EGF, FGF19, GAST, OSM, ANGPTL3, and NR2F2), risk score and clinicopathologic parameters, including patient sex, tumor grade, and TNM staging. This evidence concerns the gene ANGPTL3 and neoplasm.